NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

1972.40 13.10 (0.67%)

547.6K NSE+BSE Volume

NSE 13 Oct, 2025 3:31 PM (IST)

90,090.9

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

US FDA Approval

Lupin's facility in New Jersey, US, receives Form 483 with one observation from the US FDA See details

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Lupin Ltd.

08 Aug 2020

1972.40

0.67%

Q1FY21 Result Update - Near term multiple triggers in US, EU, specialty - BUY

Buy: Lupin Ltd.

Prabhudas Lilladhar

1QFY21 revenue and PAT was impacted due to decline of US biz (26% QoQ CC), India formulations (2% YoY) and higher effective tax rate of 60% v/s 25% QoQ. Sequential decline in US (Gx) was led by Metformin (extended release) recall, seasonality effect and normalization of sales as 4QFY20 had stocking benefits. While India formulations were impacted due to lockdown, we continue to remain positive on LPC and believe 1QFY21 was one-off...

Lupin Ltd. is trading above its 100 day SMA of 1955.0

Lupin Ltd.

08 Aug 2020

1972.40

0.67%

Lupin (ADD): Weak quarter; multiple near-term catalysts

Accumulate: Lupin Ltd.

Target

BOB Capital Markets Ltd.

Lupin's (LPC) Q1 revenue/EBITDA were 12%/14% below estimates.

Lupin Ltd. is trading above its 100 day SMA of 1955.0

Lupin Ltd.

26 Jul 2020

1972.40

0.67%

Lupin

Sell: Lupin Ltd.

Dolat Capital

R&D; investment dips to 10% of revenue since peak of 13.5% in FY17 Investments in R&D; was largely flattish in FY20 to Rs15.5bn, that is 10% of sales down from 11% in FY19 as part of cost optimization program. We highlight major products/pipeline spend of R&D;: Lupin received approval for Nepexto (biosimilar Enbrel) in Europe...

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

02 Jul 2020

1972.40

0.67%

Lupin Ltd

Sell: Lupin Ltd.

Karvy

Outlook & Valuation: We downgrade our revenue estimates by 7.5% for FY21E to Rs 169.6 bn on accountof downgrade across regions while we introduce FY22E revenue estimates atRs 186 bn.

Lupin Ltd. is trading above its 100 day SMA of 1955.0

Lupin Ltd.

05 Jun 2020

1972.40

0.67%

First Light | Bharat Petroleum Corp, Aurobindo Pharma, Lupin, Transport Corp of India

Accumulate: Lupin Ltd.

Recommendation

BOB Capital Markets Ltd.

BPCL: Inventory losses sink earnings. ARBP: Strong Q4; upside risk to EPS can support higher multiple. LPC: Lupin/Mylan win approval for biosimilar Enbrel in Europe. TRPC: Difficult Q4; growth recovery a few quarters away

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

04 Jun 2020

1972.40

0.67%

Lupin (ADD): Lupin/Mylan win approval for biosimilar Enbrel in Europe

Sell: Lupin Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Lupin (LPC) and partner Mylan have secured centralised marketing approval for Nepexto (biosimilar Etanercept) for European markets.

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

01 Jun 2020

1972.40

0.67%

Lupin Ltd

Sell: Lupin Ltd.

Target

Karvy

Outlook & Valuation: We downgrade our revenue estimates by 7.5% for FY21E to Rs 169.6 bn on account of downgrade across regions while we introduce FY22E revenue estimates at Rs 186 bn.

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

31 May 2020

1972.40

0.67%

Lupin Ltd

Hold: Lupin Ltd.

Target

ICICI Securities Limited

Q4FY20 revenues declined 12.7% YoY to | 3845.7 crore (I-direct estimate: | 3715 crore) mainly due to Kyowa divestment and due to 9.3% YoY decline in US revenues to | 1579.1 crore (I-direct estimate: | 1483 crore). Domestic formulations grew 13.3% YoY to | 1192.1 crore (I-direct estimate: | 1137 crore). EBITDA margins contracted 614 bps YoY to 13.7% (I-direct estimate: 13.2%) due to lower gross margins and higher employee cost. EBITDA de-grew 39.8% YoY to | 526.3 crore (I-direct estimate: | 489 crore). Exceptional items include profit on Kyowa Pharma divestment of |...

Lupin Ltd. is trading below its 150 day SMA of 1979.6

Lupin Ltd.

30 May 2020

1972.40

0.67%

Q4FY20 Result Update - Tale of two growths-India's steady growth, US's reviving growth - BUY

Buy: Lupin Ltd.

Target

Prabhudas Lilladhar

Metformin recall to be limited in few batches only We expect US business to get back on track and lead the growth for LPC over FY20-22E due to 1) resolution of Somerset, Goa and Pithampur (Unit-2) in FY21E 2) early launch of Albuterol 3) ramp up of Levothyroxyn 4) launch of complex injectables, Biosimilar and Spiriva in FY22E. LPC guided for EBITDA...

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

30 May 2020

1972.40

0.67%

Operationally weak; Outlook for niche products promising

Buy: Lupin Ltd.

Target

Motilal Oswal

30 May 2020 Revenues in 4QFY20 were down 1.1% YoY to INR38.5b (v/s est. INR41.4b), due to decline in US sales, partially offset by growth in the DF business. US sales were down 13.5% YoY to USD212m (42% of sales). APAC sales were down 16% YoY to INR1.4b (4% of sales). On the other hand, DF sales (31% of sales) were up 13.3% YoY to INR11.9b. Also, EMEA (Europe, Middle East and Africa) sales were up 7.4% YoY to INR3.5b (9% of sales).

Lupin Ltd. is trading below its 150 day SMA of 1979.6

Is Lupin Ltd. worth buying?

926 Votes:

Buy 72.79%

Sell 17.49%

Hold 9.72%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf